{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:39:31Z","timestamp":1786995571527,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.phrs.2013.10.001","type":"journal-article","created":{"date-parts":[[2013,10,27]],"date-time":"2013-10-27T17:32:24Z","timestamp":1382895144000},"page":"41-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Heart remodeling induced by adjuvant trastuzumab-containing chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2: A prospective study"],"prefix":"10.1016","volume":"78","author":[{"given":"Grzegorz","family":"Piotrowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Gawor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Bourge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadiusz","family":"Stasiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Potemski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenon","family":"Gawor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin C.","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2013.10.001_bib0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.phrs.2013.10.001_bib0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab \u2013 mechanism of action and use in clinical practice","volume":"357","author":"Clifford","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.10.001_bib0015","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0921-4410(03)21010-3","article-title":"Monoclonal antibody therapy for breast cancer: herceptin","volume":"21","author":"Finn","year":"2003","journal-title":"Cancer Chemother Biol Response Modif"},{"key":"10.1016\/j.phrs.2013.10.001_bib0020","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.10.001_bib0025","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2013.10.001_bib0030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.11-90001-4","article-title":"Adjuvant trastuzumab: a milestone in the treatment of HER-2 positive early","volume":"11","author":"Baselga","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.phrs.2013.10.001_bib0035","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.10.001_bib0040","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","article-title":"Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31","volume":"29","author":"Perez","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.10.001_bib0045","unstructured":"Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. NCCN Clinical Practice\u2122, Breast Cancer, Version 2.2011, NCCN.org, NCCN Guidelines for patients\u2122. Available at: www.nccn.com."},{"key":"10.1016\/j.phrs.2013.10.001_bib0050","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.10.001_bib0055","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.10.001_bib0060","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","article-title":"Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience","volume":"24","author":"Guarneri","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.10.001_bib0065","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy related cardiac dysfunction: time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.10.001_bib0070","unstructured":"Suter TM, Ewer MS. Trastuzumab-associated cardiotoxicity. In: Ewer MS, Yeh ET, editors. Cancer and the heart. Hamilton, British Columbia, Canada: Decker; 2006. p. 67\u201374."},{"key":"10.1016\/j.phrs.2013.10.001_bib0075","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1158\/1078-0432.CCR-09-0628","article-title":"Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training","volume":"15","author":"Haykowsky","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phrs.2013.10.001_bib0080","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.jacc.2010.11.063","volume":"57","author":"Fallah-Rad","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.phrs.2013.10.001_bib0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3747\/co.2008.199","article-title":"Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group","volume":"15","author":"Mackey","year":"2008","journal-title":"Curr Oncol"},{"key":"10.1016\/j.phrs.2013.10.001_bib0090","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/sj.bjc.6604909","article-title":"Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring","volume":"100","author":"Jones","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.phrs.2013.10.001_bib0095","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1001\/jama.292.19.2350","article-title":"Prognostic significance of left ventricular mass change during treatment of hypertension","volume":"292","author":"Devereux","year":"2004","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.phrs.2013.10.001_bib0100","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.phrs.2013.10.001_bib0105","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/eurheartj\/ehi204","article-title":"Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005). The Task Force for the Diagnosis and Treatment of CHF of the European Society of Cardiology","volume":"26","author":"Swedberg","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.phrs.2013.10.001_bib0110","unstructured":"WHO Study Group. Diabetes mellitus (technical report series 727). Geneva, Switzerland: World Health Organization; 1985."},{"key":"10.1016\/j.phrs.2013.10.001_bib0115","doi-asserted-by":"crossref","unstructured":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 2002;106:3143\u2013421.","DOI":"10.1161\/circ.106.25.3143"},{"issue":"23 suppl","key":"10.1016\/j.phrs.2013.10.001_bib0120","doi-asserted-by":"crossref","first-page":"A581","DOI":"10.1200\/jco.2006.24.18_suppl.581","article-title":"Update of cardiac dysfunction on NSABP B-31: a randomized trial of subsequential AC3paclitaxel vs. AC3paclitaxel with trastuzumab","volume":"24","author":"Geyer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.10.001_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajem.2008.11.012","article-title":"Trastuzumab (herceptin)-associated cardiomyopathy presented as new onset of complete left bundle-branch block mimicking acute coronary syndrome: a case report and literature review","volume":"27","author":"Tu","year":"2009","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.phrs.2013.10.001_bib0130","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/annonc\/mdp587","article-title":"Sudden death during adjuvant trastuzumab therapy of breast cancer","volume":"21","author":"Oliveira","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.phrs.2013.10.001_bib0135","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1524-4741.2007.00408.x","article-title":"Non-myopathic cardiac events in two patients treated with trastuzumab","volume":"13","author":"Olin","year":"2007","journal-title":"Breast J"},{"issue":"suppl. 1","key":"10.1016\/j.phrs.2013.10.001_bib0300","volume":"106","author":"Slamon","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.phrs.2013.10.001_bib0145","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10549-008-0260-6","article-title":"Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study","volume":"117","author":"Wadhwa","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.phrs.2013.10.001_bib0150","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1056\/NEJMc070065","article-title":"Cardiotoxicity of trastuzumab in clinical practice","volume":"357","author":"McArthur","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.10.001_bib0155","doi-asserted-by":"crossref","unstructured":"Russell SD, Blackwell KL, Lawrence J Krahn M, Fang T, Ahmadie R, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010;28:3416\u201321.","DOI":"10.1200\/JCO.2009.23.6950"},{"key":"10.1016\/j.phrs.2013.10.001_bib0160","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1200\/JCO.2009.26.0463","article-title":"Longer-term assessment of trastuzumab-related cardiac adverse events in the herceptin adjuvant (HERA) trial","volume":"28","author":"Procter","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.10.001_bib0165","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1054\/j.cardfail.2003.09.001","article-title":"Ventricular remodeling in heart failure: a credible surrogate endpoint","volume":"9","author":"Konstam","year":"2003","journal-title":"J Card Fail"},{"key":"10.1016\/j.phrs.2013.10.001_bib0170","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/378394a0","article-title":"Requirement for neuregulin receptor erbB2 in neural and cardiac development","volume":"378","author":"Lee","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2013.10.001_bib0175","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.phrs.2013.10.001_bib0180","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1073\/pnas.122249299","article-title":"Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy","volume":"99","author":"Ozcelik","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2013.10.001_bib0185","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1161\/01.CIR.59.3.421","article-title":"Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations","volume":"59","author":"Hammermeister","year":"1979","journal-title":"Circulation"},{"issue":"5 Pt 2","key":"10.1016\/j.phrs.2013.10.001_bib0190","first-page":"IV93","article-title":"Ventricular enlargement and reduced survival after myocardial infarction","volume":"75","author":"Pfeffer","year":"1987","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2013.10.001_bib0195","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.CIR.76.1.44","article-title":"Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction","volume":"76","author":"White","year":"1987","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2013.10.001_bib0200","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM199705083361903","article-title":"Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction","volume":"336","author":"Vasan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.10.001_bib0205","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0735-1097(99)00630-0","article-title":"Cardiac remodeling \u2013 concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling","volume":"35","author":"Cohn","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.phrs.2013.10.001_bib0210","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMp058315","article-title":"Herceptin and the heart \u2013 a molecular modifier of cardiac failure","volume":"354","author":"Chien","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.10.001_bib0215","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0735-1097(03)00943-4","article-title":"Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography","volume":"42","author":"Tsang","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.phrs.2013.10.001_bib0220","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.amjcard.2005.05.031","article-title":"Usefulness of left atrial volume in predicting first congestive heart failure in patients > or =65 years of age with well-preserved left ventricular systolic function","volume":"96","author":"Takemoto","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.phrs.2013.10.001_bib0225","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial","volume":"25","author":"Suter","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.10.001_bib0230","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3121\/cmr.2011.1020.c-b2-01","article-title":"C-B2-01: cardiotoxic chemotherapy is associated with increased heart failure risk among women with breast cancer in the cancer research network","volume":"9","author":"Bowles","year":"2011","journal-title":"Clin Med Res"},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2013.10.001_bib0235","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1007\/s12032-010-9717-7","article-title":"Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998\u20132005","author":"Du","year":"2011","journal-title":"Med Oncol"},{"key":"10.1016\/j.phrs.2013.10.001_bib0240","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1532-429X-10-5","article-title":"Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy","volume":"10","author":"Fallah-Rad","year":"2008","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.phrs.2013.10.001_bib0245","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.yjmcc.2006.08.002","article-title":"Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes","volume":"41","author":"Timolati","year":"2006","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.phrs.2013.10.001_bib0250","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.yexcr.2009.02.001","article-title":"Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes","volume":"315","author":"Pentassuglia","year":"2009","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.phrs.2013.10.001_bib0255","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.bbrc.2011.06.169","article-title":"Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death","volume":"411","author":"Singh","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.phrs.2013.10.001_bib0260","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","volume":"23","author":"Tan-Chiu","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.10.001_bib0265","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.10.001_bib0270","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1200\/JCO.2009.23.6950","volume":"28","author":"Russell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2013.10.001_bib0275","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.5114\/aoms.2011.26620","article-title":"Lipids, blood pressure, kidney \u2013 what was new in 2011","volume":"7","author":"Barylski","year":"2011","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.phrs.2013.10.001_bib0280","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.phrs.2013.01.006","article-title":"3,3\u2032-Diindolymethane ameliorates adriamycin-induced cardiac fibrosis via activation of a BRCA1-dependent anti-oxidant pathway","volume":"70","author":"Yao","year":"2013","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2013.10.001_bib0285","doi-asserted-by":"crossref","first-page":"227","DOI":"10.5114\/aoms.2012.28549","article-title":"Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for early breast cancer overexpressing human epidermal growth factor receptor type 2 \u2013 prospective study","volume":"8","author":"Piotrowski","year":"2012","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.phrs.2013.10.001_bib0290","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.phrs.2011.03.006","article-title":"Multimarker approach for heart failure management: perspectives and limitations","volume":"64","author":"Giannessi","year":"2011","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2013.10.001_bib0295","doi-asserted-by":"crossref","first-page":"261","DOI":"10.5114\/aoms.2013.34574","article-title":"Non-invasive assessment of cardiac hemodynamics in patients with advanced cancer and with chronic heart failure: a pilot feasibility study","volume":"9","author":"von Haehling","year":"2013","journal-title":"Arch Med Sci"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661813001692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661813001692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T17:17:53Z","timestamp":1596734273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661813001692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":59,"alternative-id":["S1043661813001692"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2013.10.001","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heart remodeling induced by adjuvant trastuzumab-containing chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2: A prospective study","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2013.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}